This content is in French.
Lyme disease: towards the return of a vaccine?
4 mai 2026
By Ana Espino | Published on May 4, 2026 | 4 min readLyme disease is the most common vector-borne disease in North America and Europe, caused by the bacterium Borrelia burgdorferi. Its incidence continues to rise, making it a major public health concern. However, no vaccine is currently available for humans since the withdrawal of LYMErix in 2002 due to safety concerns and insufficient uptake. The
By Ana Espino | Published on May 4, 2026 | 4 min read
Lyme disease is the most common vector-borne disease in North America and Europe, caused by the bacterium Borrelia burgdorferi. Its incidence continues to rise, making it a major public health concern. However, no vaccine is currently available for humans since the withdrawal of LYMErix in 2002 due to safety concerns and insufficient uptake.
The disease presents significant clinical variability, ranging from early flu-like symptoms to late complications affecting the joints, nervous system, or heart. This diversity, combined with a complex transmission cycle involving ticks and animal hosts, makes prevention particularly challenging.
In this context, the development of an effective, safe, and durable vaccine represents a major challenge. This systematic review and meta-analysis, recently published in Frontiers in Cellular and Infection Microbiology, aims to evaluate the most promising vaccine candidates currently under development in order to identify the most relevant strategies for future human vaccination.
Lyme disease is the most common vector-borne disease in North America and Europe, caused by the bacterium Borrelia burgdorferi. Its incidence continues to rise, making it a major public health concern. However, no vaccine is currently available for humans since the withdrawal of LYMErix in 2002 due to safety concerns and insufficient uptake.
The disease presents significant clinical variability, ranging from early flu-like symptoms to late complications affecting the joints, nervous system, or heart. This diversity, combined with a complex transmission cycle involving ticks and animal hosts, makes prevention particularly challenging.
In this context, the development of an effective, safe, and durable vaccine represents a major challenge. This systematic review and meta-analysis, recently published in Frontiers in Cellular and Infection Microbiology, aims to evaluate the most promising vaccine candidates currently under development in order to identify the most relevant strategies for future human vaccination.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Tamanna S, et al. Revolutionizing Lyme disease vaccination: a systematic review and meta-analysis of promising candidates. Front Cell Infect Microbiol. 2025 Apr 25;15:1554360.
View the source
